Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexeo Therapeutics (LXEO) Cash & Equivalents: 2022-2023

  • Lexeo Therapeutics' Cash & Equivalents fell 62.35% to $35.4 million in Q3 2023 from the same period last year, while for Sep 2023 it was $35.4 million, marking a year-over-year decrease of 62.35%. This contributed to the annual value of $77.3 million for FY2022, which is N/A change from last year.
  • According to the latest figures from Q3 2023, Lexeo Therapeutics' Cash & Equivalents is $35.4 million, which was down 54.16% from $77.3 million recorded in Q4 2022.
  • Lexeo Therapeutics' Cash & Equivalents' 5-year high stood at $94.2 million during Q3 2022, with a 5-year trough of $35.4 million in Q3 2023.
  • For the 2-year period, Lexeo Therapeutics' Cash & Equivalents averaged around $69.0 million, with its median value being $77.3 million (2022).
  • Data for Lexeo Therapeutics' Cash & Equivalents shows a maximum YoY tumbled of 62.35% (in 2023) over the last 5 years.
  • Lexeo Therapeutics' Cash & Equivalents (Quarterly) stood at $77.3 million in 2022, then slumped by 62.35% to $35.4 million in 2023.
  • Its Cash & Equivalents was $35.4 million in Q3 2023, compared to $77.3 million in Q4 2022 and $94.2 million in Q3 2022.